12,372 trials
Meningococcal Infection
Primary: Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at…
Attention Impairment
Primary: Change From Baseline in the Test of Variables in Attention-Continuous Performance Test (TOVA-CPT) "D-prime" Standard Score (SS) at Week 12 — 5.2; 4.5 d-prime — p=0.694
Anesthesia
Primary: Change in Base Deficit — -1.5; -1.2; -0.5 mEq/L
Pulmonary Hypertension, Familial Persistent, of the Newborn
Primary: Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure — 4.1; 4.1 days — p=0.9850
Hemophilia · Bone Disease
Primary: Bone Biomarker Density (BMD) — -0.74; -0.16; -0.16 Z-Score
Neonatal Abstinence Syndrome
Primary: Length of Treatment — 15; 28 days — p=<0.05
Dyslipidemia
Primary: Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment — -48.2; -43.6; -42.0; 2.6 percent change
Interstitial Pneumonitis · Polymyositis · Dermatomyositis
Primary: Overall Survival — 88.0 percentage of participants
Nasal Polyps · Chronic Rhinosinusitis
Primary: Change From Baseline in Nasal Polyp Score (NPS) at Week 24 — 0.06; -1.08 Score on a scale — p=<0.0001
Non-Infectious Uveitis
Primary: Proportion of Subjects With Recurrence of Uveitis in the Study Eye and Overall Summary of Number of Participants With Ocular Treatment-Emergent Adverse Events for the…
Hypertension, Pulmonary
Primary: Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters — 36.60; 60.48 Meters
Nasal Polyps · Chronic Rhinosinusitis
Primary: Change From Baseline in Nasal Polyp Score (NPS) at Week 24 — -0.31; -0.90 Score on a scale — p=0.0140
Pain Management
Primary: The Sum of Pain Intensity Differences (SPID) Through 48 Hours Post First Dose — -122.8; -110.9; -97.8 score on a scale — p=<.005
Menopause
Primary: Vaginal Cytokines at Baseline — 2.73; 3.19; 0.12; 0.04 pg/ug protein
MRSA
Primary: Number of Participants With MRSA Carriage at 1 Week Post Decolonization With Retapamulin or Placebo — 2; 13 Participants — p=0.0004